Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03983382 · ClinicalTrials.gov registry record
A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
A clinical trial of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 190
- Enrollment target
- 8
- Study locations
NCT03983382: Active study of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03983382 is a study of Breast Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 190 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03983382, a study of Breast Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 190 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Left Ventricular Ejection Fraction
Study Locations (8)
New York
- Memorial Sloan Kettering Cancer Center @ Commack (Consent and Follow up) - Commack
- Memorial Sloan Kettering Westchester (Consent and Follow-up) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Consent and Follow-up) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Cancer Center @ BaskingRidge (Consent and follow-up only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent and Follow up) - Middletown
- Memorial Sloan Kettering Bergen (Consent and follow-up only) - Montvale
Connecticut
- Hartford Healthcare Cancer Institute @ Hartford Hospital (Data collection only) - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03983382
The ClinicalTrials.gov registry entry for NCT03983382 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Left Ventricular Ejection Fraction is the first listed.
NCT03983382 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03983382 about?
NCT03983382 is a clinical study titled "A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients". The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.
What is the current status of trial NCT03983382?
This trial is currently active not recruiting. The enrollment target is 190 participants. The study started on 2019-03-22. Estimated completion is 2026-03.
What conditions does trial NCT03983382 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03983382?
The interventions under investigation include: Left Ventricular Ejection Fraction (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03983382?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03983382 being conducted?
This trial has 8 study locations across Connecticut, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.